Lipocine is a specialty pharmaceutical company developing pharmaceutical products using its oral drug delivery technology in the areas of men's and women's health. The Company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is LPCN 1021, an oral testosterone replacement therapy.
Type | Public | |
Founded | 1997 | |
HQ | Salt Lake City, UT, US | Map |
Website | lipocine.com |
USD | |
---|---|
Net income (Q2, 2020) | (6.4m) |
EBIT (Q2, 2020) | (4.2m) |
Market capitalization (19-Jan-2021) | 115.6m |
Closing stock price (19-Jan-2021) | 1.8 |
Cash (30-Jun-2020) | 13.8m |
EV | 108.1m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 428.0k | 165.0k | ||||||||||||||||||||||||
General and administrative expense | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 1.2m | 1.9m | 1.0m | 871.8k | 1.1m | 1.1m | 1.7m | 4.4m | 3.2m | 1.4m | 1.8m | 2.0m | 2.7m | 1.7m | 1.7m | 930.1k | 1.2m | 1.4m | 1.4m | 2.1m | 2.0m |
R&D expense | 1.6m | 3.4m | 6.0m | 3.2m | 1.9m | 3.2m | 4.7m | 2.7m | 2.6m | 1.5m | 3.1m | 4.1m | 2.0m | 1.4m | 1.5m | 1.4m | 1.9m | 2.0m | 1.7m | 2.5m | 2.3m | |||||
Operating expense total | 2.2k | 3.3k | 5.7k | 3.2k | 6.3k | 2.8m | 5.3m | 7.0m | 4.1m | 3.0m | 4.3m | 6.5m | 7.1m | 5.9m | 3.3m | 5.0m | 6.2m | 4.8m | 3.1m | 3.2m | 2.4m | 3.1m | 3.4m | 3.1m | 4.6m | 4.2m |
USD | Q1, 2012 | Q2, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 17.9k | 3.4k | 622.0 | 458.0 | 10.0 | 36.8m | 41.8m | 34.2m | 31.7m | 24.8m | 38.3m | 23.9m | 14.1m | 12.4m | 4.7m | 6.9m | 16.6m | 9.3m | 8.6m | 1.6m | 4.8m | 8.2m | 3.7m | 6.7m | 15.1m | 13.8m |
Prepaid Expenses | 251.7k | 256.4k | 1.3m | 285.9k | 186.5k | 181.3k | 347.8k | 268.9k | 154.0k | 457.4k | 262.0k | 88.6k | 453.4k | 248.0k | 113.3k | 728.5k | 411.4k | 148.9k | 754.5k | 373.4k | 147.3k | |||||
Current Assets | 622.0 | 458.0 | 10.0 | 37.1m | 42.0m | 35.4m | 32.0m | 25.0m | 44.1m | 42.3m | 38.6m | 33.2m | 29.4m | 27.1m | 27.9m | 26.1m | 31.6m | 25.3m | 22.6m | 23.0m | 19.6m | 17.3m | 21.0m | 23.5m | ||
PP&E | 34.8k | 27.6k | 24.6k | 40.7k | 82.7k | 79.9k | 82.9k | 108.3k | 119.9k | 111.7k | 96.3k | 89.3k | 82.2k | 32.3k | 27.9k | 23.4k | 15.1k | 11.3k | 7.4k | 2.8k | 2.0k |
USD | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|---|
Net Income | (76.7k) | (10.6m) | (20.4m) | (18.2m) | (19.0m) | (21.0m) | (11.7m) | (13.0m) |
Depreciation and Amortization | 21.8k | 14.6k | 26.7k | 32.0k | 28.4k | 18.6k | 15.4k | |
Accounts Payable | 4.3k | 668.8k | (449.6k) | 200.8k | (261.2k) | 352.2k | 73.2k | 511.0k |
Cash From Operating Activities | (62.9k) | (8.6m) | (17.3m) | (15.4m) | (18.3m) | (16.7m) | (12.1m) | (11.7m) |
USD | Q1, 2012 | Q3, 2012 | Q1, 2013 | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (4.8k) | (71.7k) | (3.2k) | (6.3k) | (6.2m) | (5.3m) | (12.2m) | (16.3m) | (3.0m) | (7.2m) | (13.6m) | (7.0m) | (12.8m) | (16.0m) | (4.9m) | (11.0m) | (15.7m) | (2.7m) | (6.0m) | (8.4m) | (3.2m) | (6.7m) | (9.7m) | (5.8m) | (12.1m) |
Depreciation and Amortization | 15.7k | 3.0k | 6.1k | 9.4k | 4.3k | 8.7k | 19.6k | 6.7k | 15.5k | 23.7k | 7.1k | 14.2k | 21.3k | 5.3k | 9.7k | 14.2k | 3.9k | 7.7k | 11.6k | 799.0 | 1.6k | ||||
Accounts Payable | (612.0) | 3.1k | 5.7k | 1.1m | (254.0k) | (385.2k) | (627.9k) | 73.3k | 30.1k | 150.6k | 570.1k | 482.0k | 357.9k | 607.6k | 867.9k | 557.9k | (209.7k) | (191.5k) | (358.1k) | (153.6k) | (555.2k) | 689.2k | 472.7k | (275.4k) | |
Cash From Operating Activities | (5.1k) | (62.8k) | (119.0) | (567.0) | (4.5m) | (3.5m) | (11.1m) | (13.6m) | (3.0m) | (6.9m) | (12.4m) | (6.5m) | (11.7m) | (15.7m) | (3.1m) | (7.8m) | (12.4m) | (3.7m) | (6.5m) | (9.8m) | (3.0m) | (5.6m) | (8.4m) | (3.4m) | (7.5m) |
When was Lipocine founded?
Lipocine was founded in 1997.
Who are Lipocine key executives?
Lipocine's key executives are Mahesh V. Patel, Morgan Brown and Greg Bass.
How many employees does Lipocine have?
Lipocine has 12 employees.
What is Lipocine revenue?
Latest Lipocine annual revenue is $165 k.
What is Lipocine revenue per employee?
Latest Lipocine revenue per employee is $13.7 k.
Who are Lipocine competitors?
Competitors of Lipocine include Rapafusyn Pharmaceuticals, Evrys Bio and Pherecydes Pharma.
Where is Lipocine headquarters?
Lipocine headquarters is located at 675 Arapeen Dr #202, Salt Lake City.
Where are Lipocine offices?
Lipocine has offices in Salt Lake City and Trenton.
How many offices does Lipocine have?
Lipocine has 2 offices.
Receive alerts for 300+ data fields across thousands of companies